Gender-diverse breast cancer patients presented younger and often found their own tumors
A multicenter cohort drawn from 22 US academic medical centers offers one of the clearest clinical portraits yet of breast cancer in transgender, nonbinary, and other gender-diverse patients. The population was small but clinically revealing: 112 gender-diverse individuals with breast cancer, plus one patient with bilateral disease, were identified across a 33-year span of treatment. Their median age at diagnosis was 42.5 years, far younger than the comparison breast cancer population in SEER, where the median age was 62 years.
The age gap is not just a descriptive curiosity. Younger presentation changes how cancer is detected, how hereditary risk is interpreted, and how clinicians should think about screening pathways. Among the gender-diverse cohort, 51.8% detected their own cancer, a finding that carries immediate bedside implications. Self-examination remains a practical route to diagnosis in people who may not be engaged in routine age-based screening, may have irregular screening histories, or may face barriers related to dysphoria, mistrust, cost, or prior negative health care experiences.
A single clinical fact stood out: most tumors were found early.
Early-stage disease dominated the cohort, with 25.7% presenting as ductal carcinoma in situ and 45.1% as stage I disease. In parallel, tumors were overwhelmingly hormone receptor positive, with 85.7% classified as such. Progesterone receptor positivity was also more common in the gender-diverse cohort than in the SEER comparison group. That pattern matters because receptor status shapes both prognosis and treatment selection, and it raises important questions about how endocrine exposures before diagnosis may influence tumor biology, even though this study was not designed to test causality.
Hormonal exposure, family history, and germline risk shaped the clinical picture
Nearly four in ten patients, 38.4%, had used gender-affirming hormone therapy before diagnosis. The study does not establish whether hormone exposure altered cancer risk, but it does show that gender-affirming care is part of the background context for many patients who develop breast cancer. For oncologists and surgeons, that means the history cannot stop at tumor stage and receptor profile. It has to include the timing and duration of hormone use, reproductive history when relevant, and any prior breast imaging or screening trajectory.
Familial risk was also common. Sixty-eight patients, or 60.7%, reported a family history of breast cancer, and 16 patients, or 14.3%, carried a pathogenic germline variant. Those numbers support a low threshold for genetic assessment in gender-diverse patients with breast cancer, especially in younger individuals. In a population already presenting at a median age well below that of the broader breast cancer cohort, hereditary predisposition may carry outsized clinical weight. Genetic counseling, cascade testing, and risk-tailored surveillance can materially affect management for both patients and relatives.
The study also included one subgroup that deserves careful attention: patients assigned male at birth accounted for 7.1% of the gender-diverse cohort, compared with 0.7% in SEER. Even this small proportion is clinically meaningful because it reflects a population that is often invisible in routine breast cancer pathways. Delayed recognition of breast symptoms in people assigned male at birth can lead to diagnostic lag, and the higher proportion seen here suggests that breast cancer services need protocols that work across sex assigned at birth and gender identity.
Five-year breast cancer-specific survival remained high, but follow-up was still limited
With a median follow-up of 38 months, the estimated 5-year breast cancer-specific survival was 96.2%, with a 95% confidence interval of 85.3% to 99.0%. The survival estimate is reassuring, especially given the large fraction of early-stage and hormone receptor–positive disease. Those tumor features generally carry a better prognosis, and the cohort’s stage distribution likely contributed to the favorable short-term outcome. Even so, the follow-up window remains relatively short for drawing conclusions about long-term recurrence risk, late treatment toxicity, or survival differences by gender identity, hormone exposure, or access to care.
The locoregional picture is also incomplete in a way that should concern clinicians. Breast cancer outcomes in gender-diverse patients are shaped not only by tumor biology but also by the mechanics of care delivery: whether screening is offered, whether symptoms are recognized early, whether pathology workup is complete, and whether adjuvant therapy is accepted and completed. Those issues can affect recurrence patterns long after the initial diagnosis is made. This cohort suggests early detection is achievable, yet it also implies that detection is often happening through patient self-recognition rather than systematic screening.
The contrast with the SEER comparison group reinforces how distinct this population is from the broader breast cancer population. Gender-diverse patients were younger, more often assigned male at birth, more likely to have progesterone receptor–positive tumors, and more likely to present with DCIS or stage I disease. Those are not trivial differences. They point toward a clinical phenotype that may reflect a mix of biology, surveillance patterns, family history, and the realities of accessing care in a system not designed around gender diversity.
Prospective studies will need to answer questions this cohort cannot resolve. Screening strategies for people at elevated risk need to be defined more precisely, especially for those using gender-affirming hormones or those who may not fit standard screening age thresholds. Long-term outcomes, locoregional recurrence patterns, and treatment tolerance also remain uncertain. For now, the most actionable message is direct: breast cancer does occur in gender-diverse patients across a wide range of identities and birth-assigned sex categories, and earlier recognition may be possible when clinicians ask the right questions and offer screening that matches risk rather than assumption.